Use of Recombinant Human Erythropoietin (r-HuEPO) in a Jehovahʼs Witness Refusing Transfusion of Blood Products

Abstract
Recombinant human erythropoietin (r-HuEPO) administration to a Jehovah's witness refusing blood transfusions increased her nadir packed cell volume from 13% to 37% and reticulocyte count from 2% to 17.7%. R-HuEPO may provide an alternative safe and effective therapy in life-threatening anemia when blood transfusions are unacceptable to the patient.

This publication has 0 references indexed in Scilit: